Skip to contentS
Sunshine Biopharma Inc.
S
SBFMSunshine Biopharma Inc. Q1 2022 · 10-Q
Revenue$122.65K$122.65K+206.2% vs Q1 2021 Net Income-$1.24M-$1.24MN/M vs Q1 2021 EPS Diluted-$0.23-$0.23no prior Q1 2021 on file Gross Profit$62,800+191.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
Operating Cash Flow-$1,304,208N/M Margins · derivedGross margin51.2%−2.6 pt vs Q1 2021
Operating margin-997.5%+2187.0 pt vs Q1 2021
Net margin-1008.0%+14432.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 6, 2022 · 36 d after period end